Cardiovascular Research Foundation
Landmark study reveals superiority of bivalirudin in heart attack patients at 30 days
Published in Hematology Week, June 2nd, 2008
MAY 21, 2008 – The Cardiovascular Research Foundation (CRF) announced that the New England Journal of Medicine published results of the HORIZONS AMI trial which showed the use of the anticoagulant bivalirudin following angioplasty in heart attack patients reduced net adverse clinical events by 24 percent compared to the standard treatment, as well as reduced the risk of overall mortality by 33 percent and cardiac mortality by 38 percent.
The study, led by Gregg Stone, M.D., Chairman of the Cardiovascular Research Foundation and professor of medicine at Columbia University Medical Center/New York-Presbyterian Hospital, compared bivalirudin to heparin plus glycoprotein...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
Source: Hematology Week (2008-06-02)
More Articles from Hematology Week
- University of California - San Diego
Ashwell receptor reduces mortality during sepsis - University of Texas Health Science Center at Houston
Blood-clotting protein modified for people with hard-to-treat hemophilia - University of Texas Health Science Center at Houston
JNC bases new guidelines for hypertension treatment with diuretics on UT research - Abruptio Placentae
New abruptio placentae research from J. Hanprasertpong and colleagues discussed - Angiogenesis
New angiogenesis research from University of Birmingham discussed - Antibiotics
Study findings from J.W. Larsen et al broaden understanding of antibiotics - More from this issue of Hematology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
